BioStem Technologies (BSEM) CAO exercises RSUs, owns 64,430 shares
Rhea-AI Filing Summary
BioStem Technologies, Inc. (BSEM) reported that Chief Accounting Officer Michael A. Fortunato exercised 970 Restricted Stock Units into 970 shares of Common Stock on August 9, 2026 at $0.00 per share, leaving him with 64,430 directly held common shares. The filing also lists multiple outstanding stock option and RSU awards with various exercise prices and vesting schedules, including options over 200,000 shares at $1.07 expiring August 16, 2027 and additional RSUs over 21,175 and 31,818 underlying shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 970 shares
Net Buy
9 txns
Insider
FORTUNATO MICHAEL A
Role
Chief Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F6, F8 | 970 | $0.00 | $0.00 |
| Exercise | Common Stock | 970 | $0.00 | $0.00 |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F4 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F5 | -- | -- | -- |
| holding | Restricted Stock Units F6, F7 | -- | -- | -- |
| holding | Restricted Stock Units F6, F9 | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 59,783 shares (Direct);
Common Stock — 64,430 shares (Direct);
Stock Options (Right to Buy) — 352,468 shares (Direct)
Footnotes (9)
- F1. These options are fully vested and exercisable.
- F2. These options vest according to the following schedule: 25% vested on January 4, 2024, with the remaining options vesting in equal monthly installments over the subsequent three year period.
- F3. These options vest with the following schedule: 33% vested on May 9, 2026, with the remaining options vesting in equal quarterly installment over the subsequent two year period.
- F4. These option vest with the following schedule: 33% will vest on October 13, 2026, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F5. These options vest with the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F6. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F7. These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024).
- F8. These restricted stock units vest according to the following schedule: 33% vested on May 9, 2026, with the remaining units vesting in equal quarterly installments over the subsequent two year period. Due to an administrative error, the vesting of the restricted stock units was not timely reported on a Form 4 within two business day of the applicable transaction date.
- F9. These restricted stock units vest according to the following schedule: 33% vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Key Figures
RSUs exercised: 970 shares
Common Stock holdings after transaction: 64,430 shares
Stock options exercise price: $1.07 per share
+5 more
8 metrics
RSUs exercised
970 shares
Restricted Stock Units converted into Common Stock on August 9, 2026
Common Stock holdings after transaction
64,430 shares
Directly held by Michael A. Fortunato following the August 9, 2026 transaction
Stock options exercise price
$1.07 per share
Options expiring August 16, 2027 over 200,000 underlying shares
Underlying shares for $1.07 options
200,000 shares
Stock Options (Right to Buy) expiring August 16, 2027
Stock options exercise price
$2.99 per share
Options expiring January 4, 2033 over 100,000 underlying shares
Underlying shares for $2.99 options
100,000 shares
Stock Options (Right to Buy) expiring January 4, 2033
Outstanding RSUs grant 1
21,175 underlying shares
Restricted Stock Units representing contingent rights to common stock
Outstanding RSUs grant 2
31,818 underlying shares
Restricted Stock Units representing contingent rights to common stock
Key Terms
Restricted Stock Units, Stock Options (Right to Buy), contingent right, equal quarterly installments, +1 more
5 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with specified exercise prices and expirations"
contingent right financial
"represents a contingent right to receive one share of the issuer's common"
equal quarterly installments financial
"vesting in equal quarterly installments over the subsequent two year period"
administrative error financial
"Due to an administrative error, the vesting of the restricted stock units"
FAQ
What transaction did BSEM insider Michael A. Fortunato report on this Form 4?
Michael A. Fortunato reported exercising 970 Restricted Stock Units into 970 shares of BioStem Technologies common stock on August 9, 2026 at a price of $0.00 per share, as an exercise or conversion of a derivative security.
What stock options does Michael A. Fortunato hold in BSEM according to this filing?
He holds several stock option awards, including options over 200,000 underlying shares at an exercise price of $1.07 expiring August 16, 2027, and options over 100,000 shares at $2.99 expiring January 4, 2033, plus additional grants at higher exercise prices and later expirations.
What Restricted Stock Units (RSUs) in BSEM remain outstanding for Michael A. Fortunato?
Outstanding RSU positions include awards over 21,175 underlying shares and 31,818 underlying shares of BioStem Technologies common stock, each RSU representing a contingent right to receive one share of common stock, subject to their respective vesting schedules.
Were the reported BSEM transactions under a Rule 10b5-1 trading plan?
No. The Form 4 indicates the Rule 10b5-1 checkbox is not marked as true, and there is no footnote stating that the August 9, 2026 transactions were made pursuant to a Rule 10b5-1 trading plan.
What does the footnote about RSU vesting and administrative error disclose for BSEM?
A footnote explains that certain RSUs vested with 33% on May 9, 2026 and remaining units in quarterly installments over two years, and notes that vesting was not timely reported on a Form 4 within two business days due to an administrative error.
AI-generated analysis. How Rhea-AI works. Not financial advice.
